Key Insights

Highlights

Success Rate

94% trial completion (above average)

Published Results

19 trials with published results (20%)

Research Maturity

59 completed trials (63% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

4.3%

4 terminated out of 94 trials

Success Rate

93.7%

+7.1% vs benchmark

Late-Stage Pipeline

20%

19 trials in Phase 3/4

Results Transparency

32%

19 of 59 completed with results

Key Signals

19 with results94% success

Data Visualizations

Phase Distribution

55Total
Not Applicable (16)
P 1 (5)
P 2 (15)
P 3 (8)
P 4 (11)

Trial Status

Completed59
Unknown21
Recruiting9
Terminated4
Suspended1

Trial Success Rate

93.7%

Benchmark: 86.5%

Based on 59 completed trials

Clinical Trials (94)

Showing 20 of 20 trials
NCT07442760Recruiting

ePro Diary - HDV ( MACROLIVER )

NCT07428538Phase 3RecruitingPrimary

Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)

NCT03089983Not ApplicableCompleted

Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings

NCT04306939Suspended

Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study

NCT06395129Recruiting

Low Dead-space Injecting Equipment Distribution Program for People Who Inject Drugs in Low- and Middle-income Countries

NCT03692897Terminated

An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

NCT06571981RecruitingPrimary

Conventional Ultrasound Versus Remote Ultraportable ulTrasound in the Context of Viral Hepatitis

NCT05989958Phase 1Recruiting

The Safety ,Tolerability and Efficacy Study of HepaCure in Chinese Subjects with Acute-On-Chronic Liver Failure

NCT06761261RecruitingPrimary

Acute Hepatitis in Pediatrics

NCT02613403Phase 2TerminatedPrimary

Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)

NCT05635266Recruiting

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

NCT05563961Not ApplicableRecruitingPrimary

A Partial Randomized, Single-blind or Open-label, Dose-escalation With Multiple-dose Design Study to Evaluate the Pharmacokinetics of Acetaminophen and Its Toxic Metabolites With Panadol® and SafeTynadol® in Healthy Volunteers

NCT00001879CompletedPrimary

Collections of Blood and Stool Samples in Patients With Acute Hepatitis

NCT02275195UnknownPrimary

Immune Cell Dysfunction in Severe Alcoholic Hepatitis

NCT05557448Phase 2RecruitingPrimary

To Evaluate the Efficacy and Safety of TYNADOTE® in the Treatment of Acetaminophen Overdose

NCT06111859Not ApplicableUnknown

Effectiveness of Ultrasound in Liver Stiffness and Fat Quantification

NCT06072287Unknown

The Living With a Long-Term Condition Study

NCT01390194Completed

Rapid 10-Minute Liver MRI Protocol in Patients With Suspected Hepatocellular Carcinoma

NCT05414552Completed

ECP for Immune-related Adverse Events After Checkpoint Inhibitor Treatment

NCT05813691Unknown

Epidemiology of Occult Hepatitis C Virus Infection in Patients Born Before 1969 in the Hospital Setting: a Spontaneous Opportunistic Screening Initiative.

Scroll to load more

Research Network

Activity Timeline